AFB SUSC. AMIKACIN

This test determines the susceptibility of acid-fast bacilli (AFB), such as Mycobacterium tuberculosis, to amikacin, an aminoglycoside antibiotic. It guides effective treatment for tuberculosis (TB) and other mycobacterial infections.

It is recommended when patients are diagnosed with drug-resistant tuberculosis or atypical mycobacterial infections, to assess the effectiveness of amikacin as part of the treatment regimen.

A cultured sample from sputum or other body fluids is tested against amikacin to determine the minimum inhibitory concentration (MIC) and assess susceptibility.

Susceptibility indicates that the organism can be effectively treated with amikacin, while resistance suggests the need for alternative antibiotics.